A Phase 1/2 interventional study of Zifibancimig and Ranibizumab in Macular Degeneration, sponsored by Hoffmann-La Roche. Completed at 37 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.
Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 36th largest by enrollment of the 124 interventional ones that give a count, is the only one that started in 2020, is one of 15 in phase 1/2, and was the 113th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Austria, Czechia, Denmark and 10 more countries
Ages 50+
AO GENERIUM · Sites in Russian Federation
Ages 50+
AbbVie · Sites in United States
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 43 · Phase 3 35 · Phase 4 33
First in 2002; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 177 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 64 across the 124 interventional studies. Of the 98 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 125 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
32 studies in Macular Degeneration by Hoffmann-La Roche: 3 open now, 10 under way, 4 of them phase 3. Of 21 finished, 10 (48%) have results posted.
Among the 32 studies in Macular Degeneration by Hoffmann-La Roche, this one is the 18th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2020, is one of 3 in phase 1/2, and was the 18th registered.
Hoffmann-La Roche’s Macular Degeneration studies by the year they started, since 2002.
3 of the studies testing ranibizumab in Macular Degeneration that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT04853251Genentech, Inc.A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 125 studies testing ranibizumab in Macular Degeneration, from their registry updates:
Among Hoffmann-La Roche’s 32 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the port delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD).
Part 1, Part 2 and Part 3
Inclusion Criteria:
Part 1 and Part 2
Ocular Inclusion Criteria for Study Eye:
Part 3
Ocular Inclusion Criteria for Study Eye:
Ocular Exclusion Criteria for Study Eye:
Exclusion Criteria for Fellow Eye
Exclusion Criteria for Either Eye
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zifibancimig administered in multiple ascending dose levels through IVT injections.
Drug: Zifibancimig
Zifibancimig administered at a high dose through the PD implant, followed by ranibizumab, 100 milligrams per milliliter (mg/mL), administered through the PD implant.
Drug: Zifibancimig · Drug: Ranibizumab · Device: Port Delivery Platform
Zifibancimig administered at a low dose through the PD implant, followed by ranibizumab, 100 mg/mL, administered through the PD implant.
Drug: Zifibancimig · Drug: Ranibizumab · Device: Port Delivery Platform
Zifibancimig administered at a high dose through the PD implant, followed by ranibizumab, 100 mg/mL, administered through PD implant.
Drug: Zifibancimig · Drug: Ranibizumab · Device: Port Delivery Platform
Zifibancimig administered at a low dose through the PD implant, followed by ranibizumab, 100 mg/mL, administered through PD implant.
Drug: Zifibancimig · Drug: Ranibizumab · Device: Port Delivery Platform
100 mg/mL of ranibizumab administered through the PD implant.
Drug: Ranibizumab
Part 1: multiple ascending doses by IVT injection. Each participant will receive zifibancimig at a constant volume of 50 microliter (µL) in the study eye. Part 2: participants will be randomized to one of two dose levels of zifibancimig in the PD implant. Part 3: Participants will receive one of the two dose levels of zifibancimig in the PD implant.
Also known as: RO7250284
Participants will receive ranibizumab 100 mg/mL through the PD implant
Participants will receive intraocular refillable device that is surgically inserted into the eye for continuous delivery of drugs into the vitreous.
Percentage of Participants With Ocular and Systemic (Non-ocular) Adverse Events (AEs)
Time frame: Part 1: Baseline up to Week 24; Parts 2 & 3: Baseline up to Week 48
Percentage of Participants With Ocular AEs During the Post-operative and Follow-up Periods
Time frame: Parts 2 and 3: From Day 1 to Week 4 and during follow-up period (up to Week 48)
Percentage of Participants With Adverse Events of Special Interest (AESIs) Including Ocular AESIs
Time frame: Part 1: Baseline up to Week 24; Parts 2 and 3: Baseline up to Week 48
Percentage of Participants With Ocular AESIs During the Post-operative and Follow-up Periods
Time frame: Parts 2 and 3: From Day 1 to Week 4 and during follow-up period (up to Week 48)
Duration of Ocular AESIs
Time frame: Part 1: Baseline up to Week 24; Parts 2 and 3: Baseline up to Week 48
Duration of Ocular AESIs During the Post-operative and Follow-up Periods
Time frame: Parts 2 and 3: From Day 1 to Week 4 and during follow-up period (up to Week 48)
Percentage of Participants With Adverse Device Effects (ADEs)
Time frame: Parts 2 and 3: Baseline up to Week 48
Duration of ADEs
Time frame: Parts 2 and 3: Baseline up to Week 48
Percentage of Participants With Anticipated Serious ADEs (ASADEs)
Time frame: Parts 2 and 3: Baseline up to Week 48
Duration of ASADEs
Time frame: Parts 2 and 3: Baseline up to Week 48
Change From Baseline in Early Treatment Diabetic Retinopathy Study - Best Corrected Visual Acuity (ETDRS-BCVA) Score at Week 48
ETDRS-BCVA will be used to quantify visual acuity. BCVA is measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.
Time frame: Part 3: Baseline (baseline visit, before implant insertion), and Week 48
Maximum Observed Concentration (Cmax) of Zifibancimig in Blood and Aqueous Humor (AH)
Time frame: Part 1: Baseline up to Week 24; Parts 2 and 3: Baseline up to Week 144
Time of Maximum Concentration Observed (Tmax) of Zifibancimig in Blood and AH
Time frame: Part 1: Baseline up to Week 24; Parts 2 and 3: Baseline up to Week 144
Concentration at the End of a Dosing Interval Before the Next Dose Administration (Ctrough) of Zifibancimig in Blood and AH
Time frame: Part 1: Baseline up to Week 24; Parts 2 and 3: Baseline up to Week 144
Area Under the Curve (AUC) of Zifibancimig in Blood and AH
Time frame: Part 1: Baseline up to Week 24; Parts 2 and 3: Baseline up to Week 144
Percentage of Participants Who did not Meet Supplemental Treatment Criteria for the PD Implant With Zifibancimig
Time frame: Part 3: Week 36, Week 40, and Week 44
Percentage of Participants Who Gained or Lost ≥15, ≥10 ≥5 or ≥0 Letters in ETDRS-BCVA Score From Baseline to Week 48
ETDRS-BCVA will be used to quantify visual acuity. BCVA is measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.
Time frame: Part 3: Baseline to Week 48
Change From Baseline in Central Subfield Thickness (CST) at Week 48
Time frame: Part 3: Baseline, and Week 48
Change From Baseline Over Time in CST
Time frame: Part 3: Baseline to end of follow-up period (up to Week 144)
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
No publications or documents are linked to this record.
Ran from Oct 2020 to primary completion in Aug 2026, 69 months.
Of 52 phase 1/2 interventional studies under Macular Degeneration, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's 69 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab